Pethema Multiple Myeloma 2000

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study objectives are to investigate the toxicity and the BUMEL response rate; in patients who reach the CR after autotransplantation, investigate if negativization of IF, influences in disease evolution; in patients in PR after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the CR with the first transplantation; Patients with MM primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation

Criteria

Inclusion Criteria:

• Less 70 years

• ECOG 0-2

• Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine >2 mg/dl).

• No previous chemotherapy

Exclusion Criteria:

• >70 years

• ECOG 3-4

• myeloma quiescent

• cardiopathy

• liver disfunction

• HIV+

• Hepatitis B-C +

• Previous chemotherapy